Hoth Therapeutics, Inc. announced that it has received written approval from the GW University Hospital, UC Irvine and Northwell Health to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi). This Phase 2a dose- ranging study to investigate the efficacy, safety, and tolerability of topical HT-001 for the treatment of skin toxicities associated with EGFRi.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.93 USD | +5.68% |
|
+4.73% | -35.42% |
07-16 | Hoth Therapeutics, Inc. Expands Clinical Trial for Cancer Patients | CI |
05-14 | Hoth Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.42% | 4.98M | |
+61.53% | 848B | |
+33.08% | 627B | |
-3.66% | 363B | |
+15.06% | 318B | |
+9.18% | 299B | |
+13.57% | 243B | |
+16.12% | 225B | |
+15.67% | 179B | |
+2.47% | 167B |
- Stock Market
- Equities
- HOTH Stock
- News Hoth Therapeutics, Inc.
- Hoth Therapeutics, Inc. Expands Clinical Trial for Cancer Patients